Global Infectious Disease Diagnostics Market Driven by Evolving Pathogens and Increasing HAIs

Immediate diagnosis of infectious disease is the present need of the time due to evolving pathogens and increasing occurrence rate of hospital-acquired infections. The global COVID-19 pandemic has also boosted the demand for laboratory-based molecular testing capacity and reagents. Companies have been working on developing commercial and in-house assays that can identify COVID-19. Governments across the world have also been emphasizing on rapid diagnosis of infectious disease as a strategic priority. As a result, the global infectious disease diagnostics market is projected to surpass USD 28 billion by 2027.

These are the latest findings of Reports and Data (New York City, NY, USA), a market research and consulting company.

The development of commercial and in-house assays that identify COVID-19 is expected to contribute to the growing demand for molecular microfluidics diagnostics. Technological advancements, development of microfluidic-based solutions by various market players, and the scope for automation of complex sample preparations on microchips and reliability associated with it in detecting pathogens will result in surging demand. This will also boost the demand for respiratory testing. Several industry players have been focusing on developing respiratory tests for COVID-19 that would also be applicable for other respiratory pathogens such as influenza A and B. This will further drive the growth of the global infectious disease diagnostics market.

Based on product type, the consumables segment is expected to witness the highest growth due to rising demand for assays and reagents as a result of the growing demand for IDD tests. The increasing occurrence of infectious diseases such as COVID-19 and a growing geriatric population is resulting in increasing demand for IDD tests. In addition, the COVID-19 pandemic is resulting in the development of various commercial and in-house assays to detect the virus, which will also contribute to the segment’s growth.

Based on technology, the molecular diagnostic technique segment is expected to witness the fastest growth, driven by the increasing demand for polymerase chain reaction (PCR) and isothermal nucleic acid amplification tests. Furthermore, the development of assays using this technology such as molecular assays, the use of which is supported by WHO, will also contribute to the segment’s growth. Based on disease type, the hepatitis segment will continue to hold the largest market share due to the growing adoption of developed technologies for hepatitis B diagnosis and high occurrence of the condition, particularly among individuals below 40 years.

Visit expo >

Gold Member

Chagas Disease Test

CHAGAS Cassette

Verification Panels for Assay Development & QC
Seroconversion Panels

New

Toxoplasma Gondii Immunoassay

Toxo IgM AccuBind ELISA Kit

New

Multi-Function Pipetting Platform

apricot PP5